New combo pill aims to tackle diabetes and fatty liver at once
NCT ID NCT07289750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 4 trial will test whether adding alogliptin to a standard two-drug regimen (pioglitazone and metformin) improves blood sugar control and liver health in 80 adults with type 2 diabetes and fatty liver disease. Participants must not have used diabetes medications in the past six months. The study compares the three-drug combo against the two-drug combo alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alogliptin, pioglitazone, and metformin hydrochloride tablets
- What this could lead to
- If successful, this could point to a more effective combination therapy for managing both type 2 diabetes and fatty liver disease.
- What could go wrong
- This is a small, early-phase trial (80 participants) that has not yet started. The added benefit of alogliptin may be modest, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a malaria drug melt liver fat? new trial investigates
- New diabetes pill HRS9531 enters Mid-Stage trial – could it help control blood sugar?
- Reishi mushroom tested as fatty liver treatment in new study
- New diabetes drug HM15275 enters Mid-Stage trial
- Gut health and gym: new combo tackles fatty liver
- Fatty liver mystery: 1,000 rural bangladeshis to be screened